The ENCIRCLE Trial
← catalyst calendarNCT04153292 · readout in 193 d
Sponsored by Edwards Lifesciences (industry) · EW — their whole pipeline →.
Phase
Not applicable
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
900estimated
Sites
68
Countries
Australia, Canada, Israel +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-11-12 | actual | When the study began enrolling |
| Primary completion | 2027-02-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2019-11-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Mitral Regurgitation
- Mitral Valve Insufficiency
Intervention
- Device: SAPIEN M3 valve and dock
Primary outcome
what the primary-completion date above is the date OFNon-hierarchical composite of death and heart failure rehospitalization
measured 1 year
Publications
- PMID 41167201 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · EW's whole pipeline · Catalyst calendar · Every registered study · What changed